U.S. markets close in 2 hours 3 minutes

Glaukos Corporation (GKOS)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
56.21+3.15 (+5.94%)
As of 01:56PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close53.06
Bid56.34 x 900
Ask56.41 x 900
Day's Range55.55 - 56.88
52 Week Range33.33 - 64.49
Avg. Volume573,529
Market Cap2.684B
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.59
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GKOS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Glaukos Corporation
    GKOS: Lowering target price to $42.00GLAUKOS CORP has an Investment Rating of SELL; a target price of $42.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • InvestorPlace

    The 3 Most Aggressive Growth Stocks to Buy Now

    Wall Street is getting ready to welcome the fourth quarter, which will see companies report earnings. Meanwhile, many economists are warning the odds of a recession are increasing. Against this backdrop, investors are searching for the most aggressive growth stocks to buy amid the volatility. According to Golden Eagle Strategies, $100 invested in aggressive growth funds would have grown to about $170,100 from 1958 to 2021. However, “the same $100 investment in the S&P 500 would have grown to app

  • Business Wire

    Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

    ALISO VIEJO, Calif., September 28, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30 - October 3, 2022 in Chicago, IL.

  • Zacks

    Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

    Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.